logo

EVAX

Evaxion·NASDAQ
--
--(--)
--
--(--)

EVAX fundamentals

Evaxion (EVAX) released its earnings on Mar 5, 2026: revenue was 0 (YoY -100.00%), met estimates; EPS was -0.02 (YoY +71.43%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.02
+71.43%
Report date
Mar 5, 2026
EVAX Earnings Call Summary for Q4,2025
  • Clinical Breakthroughs: EVX-01 melanoma vaccine shows 75% ORR with 81% T-cell response rate; EVX-04 AML vaccine targets novel ERV antigens.
  • Financial Strength: $23M cash runway to H2 2027; reduced net loss to $7.7M with improved operational efficiency.
  • Strategic Expansion: AI-Immunology platform enters autoimmune space; EVX-B2 gonorrhea vaccine attracts partner interest post-MSD evaluation.
  • 2026 Milestones: Submit EVX-04 IND, share EVX-01 3-year data, and advance autoimmune platform development.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Evaxion (EVAX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Evaxion (EVAX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Evaxion (EVAX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Evaxion (EVAX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Evaxion (EVAX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Evaxion (EVAX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield